With a better understanding of how NETs form and the role PAD4 plays in the process, it is possible to find ways of controlling NET-associated diseases such as systematic lupus erythematousus (SLE), deep venous thrombosis (DVT), preeclampsia, etc. As we have recently shown that the newly developed PAD4 inhibitors could serve as putative cancer therapeutics (Wang et al., 2012), inhibiting PAD4 could offer a new strategy for treatment of NET associated ailments. This evidence concerns the gene PADI4 and systemic lupus erythematosus.